

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

September 11, 2020

Amitay Weiss Chief Executive Officer Therapix Biosciences Ltd. 16 Abba Hillel Silver Rd. Ramat Gan 52506, Israel

> Re: Therapix Biosciences Ltd. Registration Statement on Form F-1 Filed September 8, 2020 File No. 333-248670

Dear Mr. Weiss:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Oded Har-Even, Esq.